Stock listing

Hanover:2CL BridgeBio Pharma, Inc. Aktie

German listing (Hanover) of BridgeBio Pharma, Inc. · home listing NASDAQ:BBIO

Follow BridgeBio Pharma, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:BBIO

$66.39 USD -0.74 (-1.1%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:BBIO

BridgeBio Pharma, Inc. logo
Ticker
Hanover:2CL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Hanover
Currency
EUR

What changed lately

Calls

Replays

  • Bridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call

    Mon, Aug 10, 2026 · 4:30 PM ET

    Watch Transcript

  • BridgeBio Pharma, Inc. (BBIO) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 4:30 PM ET

    Watch Transcript

  • Bridgebio Pharma (NASDAQ:BBIO) Q4 2025 Earnings Call

    Tue, Feb 24, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Oct 16, 2026

BridgeBio to Present New Acoramidis Data, Including Independent Comparative Real-World EHR Data at the HFSA Annual Scientific Meeting 2026

Oct 6, 2026

BridgeBio to Present Additional Evidence from the Phase 3 CALIBRATE Trial of Encaleret in ADH1 at the ASBMR 2026 Annual Meeting

Oct 6, 2026

BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day

Oct 6, 2026

BridgeBio Announces FDA Acceptance and Priority Review of NDA for Oral Infigratinib for Children with Achondroplasia

Oct 6, 2026

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Oct 5, 2026

BBIO-Infigratinib-ESPE 2026-Longer Term Results

Sep 9, 2026

BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026

Sep 2, 2026

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Aug 31, 2026

BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM

Aug 26, 2026

All BridgeBio Pharma, Inc. news

Financings

  • Preferred equity

    Aug 10, 2026

    Closed: US$1B raised

    Buyers: Sixth Street (led the financing); HealthCare Royalty

    Use of proceeds: Fund three potential upcoming launches while continuing to invest in indication expansion across the pipeline

    Closed Aug 10, 2026

Read by 6ix AI from the company's releases

Decks

BridgeBio Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
58 in the last 12 months · 268 in all · newest Oct 16, 2026 · oldest 2019
Calls
6 calls with a replay · 6 with a transcript · latest Aug 10, 2026
Decks
23 decks · latest May 7, 2026

Where BridgeBio Pharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BBIO · Home listingNASDAQUnited StatesUSD
gettex:2CLgettexGermanyEUR
LS Exchange:A2PLX7LS ExchangeGermanyEUR
Tradegate:2CLTradegateGermanyEUR
Lang & Schwarz:A2PLX7Lang & SchwarzGermanyEUR
BX Swiss:BBIOBX SwissSwitzerlandCHF
Milan:1BBIOMilanItalyEUR
BOATS:BBIOBOATSUnited StatesUSD
Frankfurt:2CLFrankfurtGermanyEUR
Dusseldorf:2CLDusseldorfGermanyEUR
Hamburg:2CLHamburgGermanyEUR
Munich:2CLMunichGermanyEUR
Stuttgart:2CLStuttgartGermanyEUR
BMV:BBIOBMVMexicoMXN
Hanover:2CL · This pageHanoverGermanyEUR
Xetra:2CLXetraGermanyEUR

Log in to ask 6ix AI your own questions about BridgeBio Pharma, Inc.